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Abstract
Background: Neuropathic pain is an apparently spontaneous experience triggered by abnormal
physiology of the peripheral or central nervous system, which evolves with time. Neuropathic pain
arising from peripheral nerve injury is characterized by a combination of spontaneous pain,
hyperalgesia and allodynia. There is no evidence of this type of pain in human infants or rat pups;
brachial plexus avulsion, which causes intense neuropathic pain in adults, is not painful when the
injury is sustained at birth. Since infants are capable of nociception from before birth and display
both acute and chronic inflammatory pain behaviour from an early neonatal age, it appears that the
mechanisms underlying neuropathic pain are differentially regulated over a prolonged postnatal
period.
Results: We have performed a microarray analysis of the rat L4/L5 dorsal root ganglia (DRG), 7
days post spared nerve injury, a model of neuropathic pain. Genes that are regulated in adult rats
displaying neuropathic behaviour were compared to those regulated in young rats (10 days old)
that did not show the same neuropathic behaviour. The results show a set of genes, differentially
regulated in the adult DRG, that are principally involved in immune system modulation. A functional
consequence of this different immune response to injury is that resident macrophages cluster
around the large A sensory neuron bodies in the adult DRG seven days post injury, whereas the
macrophages in young DRG remain scattered evenly throughout the ganglion, as in controls.
Conclusions:  The results show, for the first time, a major difference in the neuroimmune
response to nerve injury in the dorsal root ganglion of young and adult rats. Differential analysis
reveals a new set of immune related genes in the ganglia, that are differentially regulated in adult
neuropathic pain, and that are consistent with the selective activation of macrophages around adult,
but not young large A sensory neurons post injury. These differences may contribute to the
reduced incidence of neuropathic pain in infants.
Background
Physiological pain is an acute experience that results from
the activation of peripheral nociceptors in injured and
inflamed tissues and which normally passes when the
stimulus ceases. In contrast, neuropathic pain is an appar-
ently spontaneous experience triggered by abnormal
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physiology of the peripheral or central nervous system,
which evolves with time. Neuropathic pain arising from
peripheral nerve injury is characterized by a combination
of spontaneous pain, hyperalgesia and allodynia and as it
is poorly relieved by conventional analgesics, it is a signif-
icant clinical problem [1]. Neuropathic pain is less com-
mon in children than in adults. Although it has been
reported in very young paediatric patients [2], there is no
evidence of this type of pain in infancy; brachial plexus
avulsion, which causes intense neuropathic pain in adults,
is not painful when the injury is sustained at birth [3].
Consistent with this, persistent mechanical allodynia does
not develop in spared nerve injury (SNI) and chronic con-
striction injury (CCI) rat models of neuropathic pain, if
the injury is performed younger than 4 weeks of age [4].
Furthermore, in the spinal nerve ligation model (SNL),
neuropathic symptoms resolve faster in younger animals
[5]. Since infants are capable of nociception from before
birth and display both acute and chronic inflammatory
pain behaviour from an early neonatal age [6], it appears
that the mechanisms underlying neuropathic pain are dif-
ferentially regulated over a prolonged postnatal period.
The mechanisms underlying neuropathic pain in adults
involve molecular and cellular changes in both the
peripheral and central nervous system to produce the
characteristic intensity and prolonged time course of the
pain [7,8]. Increased focus has been placed upon the role
of neuroimmune interactions in animal models of persist-
ent pain suggesting that the major stimulus for the under-
lying neuronal hypersensitivity in chronic pain states
involves activation of glial cells, which when stimulated,
increase production of a host of inflammatory/algesic
mediators, such as cytokines and chemokines [9,10]. In
the peripheral nervous system, primary afferent neurons
in the dorsal root ganglion (DRGs) [11] interact with two
main types of non-neuronal cells in chronic pain states:
satellite cells which surround neurons and control their
chemical environment [12] and resident macrophages
that are activated by nerve damage and inflammation [13-
15].
Our overall aim is to discover why nerve injury induced
neuropathic pain does not occur or is rapidly resolved in
young animals, while it is intense and prolonged in
adults. In the present study, we hypothesise that the post-
natal maturation of the neuropathic pain response in
young animals arises, at least in part, from developmental
changes in the response of the dorsal root ganglion to
nerve injury. To test our hypothesis, we analysed and
compared transcriptional changes in young and adult
DRGs after neuropathic nerve injury or sham controls,
using high throughput screening with the Affymetrix®
array rat203_v2. Our results reveal a new set of genes that
implicate the peripheral immune system in the regulation
of neuropathic pain. Immunohistochemical analysis of
the dorsal root ganglia after nerve injury confirmed a
selective pattern of macrophage activation that is specific
for injured neurons in adult, but not young rats.
Materials and methods
Surgery
Experiments were performed on adult (2 months old)
male Sprague-Dawley rats and rat pups (10 days postnatal
age, P10) and carried out in accordance with the United
Kingdom Animal (Scientific Procedures) Act 1986. Spared
nerve injury and sham surgery were performed under
halothane general anaesthesia with antiseptic conditions
as described previously [16]. After skin preparation, the
sciatic nerve and its three terminal branches were exposed
in the upper lateral thigh. Axotomy and ligation of the
common peroneal and tibial branches was performed
under direct vision, leaving the sural nerve intact. Retro-
grade tracer (4 μL of 4% Fluorogold, Fluorochrome®, LLC)
was injected into the cut end of the severed nerves to iden-
tify injured neurons [17]. In adult rats after SNI surgery,
92.4% ± 1 (SE) of Fluorogold labelled neurons were also
labelled with ATF-3 (which is known to mark damaged
and regenerating neurons [18]) (Additional file 1). Mus-
cle and skin were closed in two layers. In the sham opera-
tion, the procedures were the same but the nerves were
only exposed and not cut or ligated. In all cases great care
was taken not to stretch the nerve, or its branches, nor to
damage the intact nerves.
After surgery, animals were returned to their cages and lit-
ters and maintained on a 12 hour light/dark cycle at con-
stant ambient temperature with free access to food and
water for 7 days post surgery until tissue collection.
RNA extraction
Seven days post surgery, animals were sacrificed with 100
mg/kg of Euthanal®, fresh DRGs were collected, snap fro-
zen on liquid nitrogen and stored at -80°C until RNA
extraction. Both L4 and L5 DRGs ipsilateral to the lesion
were collected and pooled from 3 animals per adult exper-
imental group and 4 animals per P10 group, (i.e. n = 6
DRGs per adult sample, n = 8 per P10 sample) to mini-
mise inter-animal differences. RNA was extracted using
Trizol® reagent (Invitrogen®) and a QIAshredder column
(Qiagen®) for homogenisation according to manufac-
turer's protocols. The RNA was cleaned by an "RNA puri-
fication column" (Qiagen®) and a final volume of 50 μL
obtained. The amount of RNA was measured with a Nan-
oDrop ND-1000 Spectrophotometer (NanoDrop Technolo-
gies, Inc.) and its quality assessed with Experion RNA
HighSens StdSens analysis kit (Bio-Rad®). Then, the RNA
was precipitated and dissolved to obtain a final concentra-
tion of 1 μg/μL and stored at -80°C for cRNA synthesis orMolecular Pain 2009, 5:70 http://www.molecularpain.com/content/5/1/70
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amplification by quantitative real-time polymerase chain
reaction (qPCR).
cRNA synthesis
First strand cDNA synthesis
2 g (for qPCR) or 10 μg (microarray analysis) of total RNA
and 100 pmol/μL of the T7(dT)24 primer (5'-GGCCAGT-
GAATTGTAATACGACTCACTATAGGGA GGCGGTTTTTT
TTTTTTTTTTTTTTTTTT-3') were combined for annealing
at 60°C for 10 mins and chilled on ice for 2 mins. Then,
the SuperScript III kit (Invitrogen®) was added according
to manufacturer instructions to synthesize the cDNA.
Second strand cDNA synthesis
the whole amount of the cDNA produced was used as
template for the second strand synthesis plus 10 units of
E. coli DNA ligase, 40 units of E. coli DNA polymerase
(Invitrogen®), 3 μL of 10 mM dNTPs and 2 units of Rnase
H (Invitrogen®). The reaction was stopped by addition of
10 μL of 0.5 M EDTA. The double stranded cDNA was
then purified and precipitated and then resuspended in
10 μL of nuclease free water.
Synthesis of biotin-labelled cRNA
we used the Enzo-Bioarray kit (Enzo Life Sciences, Inc) for
synthesis of the cRNA according to the manufacturer pro-
tocol. The resulting cRNA was purified with Rneasy kit
(Qiagen®). The concentration was measured using a spec-
trophotometer and 20 μg of each sample were fragmented
in 200 mM tris-acetate (pH= 8.1), 500 mM potassium ace-
tate and 150 mM magnesium acetate for 35 mins at 95°C,
then chilled on ice and stored at -80°C until microarray
hybridisation.
Microarray analysis
cRNA hybridisation
For mRNA high-throughput screening we used GeneChip ®
Rat expression 230 version 2.0 arrays and GeneChip®Hybrid-
ization, Wash and stain kit from Affymetrix®. The hybridi-
sation protocol was in 49/64 formats, appropriate for the
selected array. The control oligonucleotides were: B2 and
the Eukaryotic bioB, bioC, bioD and cre. Then, the samples
were washed and stained on the Fluidics Station 450
(Affymetrix®) monitored with the GeneChip®Operating
Software (Affymetrix®) (protocol FS450_003 appropriate
for the rat 230 v2.0 array) and scanned with GeneChip
Scanner 3000 (Affymetrix®).
Array statistical analysis
the ".CEL" files generated with GeneChip Scanner 3000
(Affymetrix®) (see additional file 2 for details) were
acquired by "R environment for statistical computing and
graphics language software" (the GNU project) using the
BioConductor® package [19]. The expression data was nor-
malised by GC-Robust Multi-array Average (GC-RMA)
background adjustment. Limma analysis [20] was used as
a lineal method for contrasting the groups and identifying
specific genes for each experimental group.
The quality of the arrays was assessed with Affymetrix
Expression Console™ Software Version 1.0 (Affymetrix®)
using an n = 3 per experimental group. Two samples out
of 18 were outliers (Figure 1), one from P10 contralateral
group and one from the P10 injured group. These two
samples were removed from further analysis.
Quantitative Real-Time PCR
Specific primers for the gene candidates obtained from the
microarray study were designed and synthesized by
Quality assessment of the microarrays Figure 1
Quality assessment of the microarrays. The figure shows the relative expression signal of the RMA-normalised microar-
rays before (a) and after (b) removal of the outliers (*). A: adult; P: 10 day old rat; I: spared nerve injury group H: sham group 
and C: contralateral group (all 7 days after surgery).Molecular Pain 2009, 5:70 http://www.molecularpain.com/content/5/1/70
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Sigma-Genosys (Table 1). An SYBR green-based system
(Applied Biosystems) was used for amplification and
detection. 1 μL of cDNA product per sample, 12.5 μl of
Power SYBR green PCR Master Mix and 200 nM/primer
was used for cocktail reaction. The amplification protocol
was: step 1 at 95°C for 5', step 2 at 95°C for 45", step 3 at
60°C 1' step 4 at 70°C 1', step 5 plate reading, 39 cycles
from step 2 to 4 and a final melting curve from 60°C to
90°C with reading every 0.5°C and 1" hold. The reaction
plate was then placed in a DNA Engine Pelter thermal
cycler with a Chromo 4 Real-Time PCR detector (Bio-Rad®).
The amplification process was monitored with Opticon
Monitor v3.1.32 software (MJ Genework Inc).
Table 1: Primers sequences for quantitative Real-Time PCR.
Serine (or cysteine) inhibitor, clade A, member 3N Sens CAGGCAATGCCCTGTTTATT
Antisens CACGAGACTGCTGGAAATCA
Serine (or cysteine) inhibitor, clade B, member 2 Sens CACCACGCTTGGGAGATTAT
Antisens TTCATTGGCACATTCAAGGA
Interleukin-6 Sens CTTCCAGCCAGTTGCCTTCTTG
Antisens TGGTCTGTTGTGGGTGGTATCC
Mitogen-activated protein kinase kinase 6 Sens GTTGACTTTACCTCACAGTGCTTGAAG
Antisens TCCCCGAGTATCAGTTTTACGAAAGAC
Chemokine (C-C motif) ligand 2 Sens ATGCAGTTAATGCCCCACTC
Antisens TTCCTTATTGGGGTCAGCAC
Inositol 1,4,5-trisphosphate 3-kinase C Sens TGATGGCTCCCTCATAGGAC
Antisens TCACCAAGTCTCTGGGCTCT
Matrix metallopeptidase 16 Sens GGAATTGGAGGCGATACTCA
Antisens CCAGCTCATGGACTGCTACA
Monoamino oxidase A Sens AGCAAGACACGCTCAGGAAT
Antisens CCACAGGGCAGATACCTCAT
Glyceraldehyde-3-phosphate dehydrogenase Sens ACTCTACCCACGGCAAGTTC
Antisens GGTGGTGAAGACGCCAGTAG
Caspase 3 Sens CCCTCTCATTTAAATCAAATCCG
Antisens GTTCCTAATTAAATTTCATTTCAACTACC
Toll like receptor 4 Sens TCTCTTTAGACCTGTCTTTAAACC
Antisens AAGGCACATTTTCAGTACATTTG
Matrix metallopeptidase 3 Sens TTGATGAGAAGAAACAATCCATG
Antisens CGCTGAAGAAGTAAAGAAACC
Complement component3 Sens GAGCAAGCTGTGCCACAATG
Antisens GGTCTTGTACACGTAGTCCACTC
cAMP responsive element modulator Sens ATGAAACTGATGAGGAGACTGACC
Antisens GCTCGGATCTGGTAAGTTGGC
Colony stimulating factor 1 (macrophage) Sens ATCCCGTTTGCTACCTAAAG
Antisens AGCTGTTCAGTTTCATAGAGAG
Chloride intracellular channel 1 Sens TCCACGTTGCTACATAATGG
Antisens CCCTTGTCCTCTAATCTTTCC
Purinergic receptor P2Y, G-protein coupled, 14 Sens ACATACAGTGCATGGAACTC
Antisens CAGAAAATGCTCACGAAGACMolecular Pain 2009, 5:70 http://www.molecularpain.com/content/5/1/70
Page 5 of 17
(page number not for citation purposes)
The DNA products from the qPCRs were sequenced on an
AB PRISM 3100-Avant automated DNA capillary
sequencer (AB Applied Biosystems, Lingley House, 120,
Birchwood Boulevaid, Warrington) using BigDye Termi-
nator v1.1 Cycle Sequencing chemistry (AB Applied Bio-
systems). Sequencing reactions were performed and
precipitated in accordance with the manufacturer's
instructions using the same sense or forward primer that
was used for the qPCR amplification (Table 1). The reac-
tions were resolved on a 50 cm standard sequencing cap-
illary, running optimal 3100 POP-6TM polymer (AB
Applied Biosystems). Sequence data was extracted and
analysed using AB PRISM 3100-Avant Data Collection
Software v2.0 and DNA Sequencing Analysis Software
v5.1.1 respectively (AB Applied Biosystems).
Immunostaining
Seven days post surgery rats were overdosed with 100 mg/
kg of Euthanal® and perfused through the heart with 200
ml heparin-saline, followed by 200 mL 4% paraformalde-
hyde in 0.1 M phosphate buffer (PB). The lumbar ganglia
L4 and L5 were removed and postfixed in 4% paraformal-
dehyde for 1 h at 4°C followed by immersion in 30%
sucrose in 0.1 M of PB at 4°C for at least two days before
sectioning. Serial, 20 μm cryostat sections were cut and
stained after blocking in 10% normal goat serum, 0.3%
Triton X in 1× PBS using primary antibodies: Rabbit anti-
IBA-1 (1/1000, Dako®), mouse anti NF200 (1/1000,
Chemicon®), rabbit anti ATF-3 (1/500, Santa Cruz®),
mouse anti CD68/ED-1 (1/200. Serotec®), mouse anti
NG2 (1/500, Millipore®) and rabbit-anti-CGRP (1/500
Chemicon®). The antibodies were incubated overnight at
room temperature in 3% normal goat serum, 0.3% Triton
X in 1× PBS. Secondary antibodies were goat anti-mouse
(Alexa-593®) and goat anti-rabbit (Alexa-488®) at 1/200
dilution in 3% normal goat serum, 0.3% Triton X in 1×
PBS. Antibody excess was removed by 3 washes in PBS for
10' at RT. The isolectin IB-4 (Bandeira simplicifolia)
labelled with FITC (Sigma®) was used to identify the non-
peptidergic neurons. After staining, the sections were kept
for 16 h in the dark to normalize the background and then
microscope images acquired at 10× magnification with
OpenLab® software at a constant exposure time of 1.02".
Data Analysis for immunohistochemistry and qPCR
The images generated by immunohistochemistry were
analysed with Image J 1.36 (NHS) software, n = 3 rats per
experimental group, n = 4-6 sections per animal and n =
200 cells counted per section. The sections were from the
centre of the ganglion and 160 μm apart to ensure that the
same cell was not counted twice (large neurons may have
a diameter up to 100 μm). Cells were counted as having
macrophage 'ring-like' structures when the perimeter of
the neuron was surrounded by macrophages which were
closely adhered to the neuronal surface, as observed in
merged images from IBA-1 and NF200 immunostaining.
Data was pooled from animals in the same experimental
group.
Pooled qPCR data from each experimental group (n = 3
samples per group) were plotted as "mean intensity nor-
malized" (MIN) ± standard deviation (SD). The normali-
sation was calculated as the ratio with the housekeeping
gene, Gapdh. All data was exported to SigmaStat, 2.03®
(SPSS Inc®) for statistical analysis and plotted with Sigma-
Plot® (SPSS Inc®).
Results
Differential microarray screening of DRG following nerve 
injury reveals 'neuropathic pain' specific genes
We performed high throughput screening of the mRNA
regulation in L4/L5 dorsal root ganglia following spared
nerve injury (SNI) or sham injury in adult and young rats
using the Affymetrix-rat genome 230 2.0 array. We first ana-
lysed the effect of postnatal age on mRNA regulation by
comparing the two SNI groups: young, (PDI) and adult
(ADI) rats. We chose seven days post surgery for this anal-
ysis as it is known that at this time point, neuropathic
behaviour is present in adult but not in young rats [4,16].
The term 'young rats' denotes animals that were 10 days
old (P10) at the time of surgery, but whose DRGs were
collected for microarray analysis 7 days later, at P17. We
used two types of controls to extract specific information
obtained from the SNI groups: 1) sham surgery groups in
adults (AHI) and young rats (PHI) and 2) contralateral
groups in adults (ADC) and young rats (PDC).
Limma analysis was performed to compare the experi-
mental groups in two steps. First, the nerve injury specific
gene regulation in adult or young rats was compared to
their counterpart sham or contralateral groups to remove
those genes that could be up or down-regulated by the
surgery alone rather than specifically the nerve injury. The
P-value was adjusted for false discovery rate and a thresh-
old of p < 0.05 was set up to subtract those genes with sta-
tistically significant differential regulation (Additional file
2). Next, the resulting lists from both the adult and young
comparisons were compared to obtain nerve injury spe-
cific genes in adult rats only (pain behaviour) or young rats
only  (no pain behaviour). The screening provided 206
Affymetrix identifications (Affy_IDs) associated with
mRNAs specific to adult SNI rats and only 3 Affy_IDs spe-
cific to young (P10) SNI.
The 206 genes were sorted into basic functional groups
according to the "Go biological process" [21]. Figure 2A
shows that the 206 Affy_IDs were distributed in approxi-
mately equal proportions in extracellular (23%), mem-
brane (34%), nuclear (21%) and cytoplasmatic (21%)
compartments. We also grouped the genes accordingly toMolecular Pain 2009, 5:70 http://www.molecularpain.com/content/5/1/70
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"GO terms" (Figure 2B). Of the 206 genes, 39.6% (82
Affy_IDs) were related to Express Sequence tags (EST) (for
predicted genes or similarities to known genes) and
unknown genes and the rest comprised: immune system/
inflammation 18.4% (38 Affy_IDs), signal transduction
12.1% (25 Affy_IDs), nervous system 6.8% (14 Affy_IDs),
RNA/DNA modulation 5.3% (10 Affy_IDs), apoptosis/
cell cycle 4.8% (10 Affy_IDs), ion transport 1.9% (4
Affy_IDs), cell adhesion 1.9% (4 Affy_IDs) and 9.2% (19
Affy_IDs) related to other processes (additional file 3).
Neuropathic pain specific gene validation by quantitative 
Real-time PCR
From the 206 significantly regulated genes, we selected 16
that had some previous published association with pain
processes and/or immune system, (Table 2). Using the
"Go term" classification, 8 genes belonged to the
'Immune system': (Serine (or cysteine) proteinase inhibi-
tor, clade A, member 3N (SERPINA3N), interleukin 6 (IL-
6), colony-stimulating factor 1 (CSF-1), toll-like receptor
4 (TLR4), purinergic receptor P2Y, G-protein coupled, 14
(P2RY14), complement component 3 (C3), macrophage
chemoattractant protein 1 (MCP-1/CCL2) and chloride
intracellular channel 1 (CLIC-1), one gene belonged to
the 'Nervous system': monoamino oxidase A (MaoA); one
gene to 'Apoptosis': Caspase 3 (CASP3); two genes to 'Sig-
nal transduction': inositol 1,4,5-triphosphate 3-kinase C
(ITPKC) and mitogen-activated kinase kinase 6
(MAP2K6); and a further four from other groups: cAMP
responsive element modulator (CREM) to the RNA/DNA
modulation group and serine (or cysteine) proteinase
inhibitor, clade B, member 2 (SERPINB2), matrix metal-
lopeptidase 3 (MMP3) and matrix metalloproteinase 16
(MMP16).
To validate the microarray results of these 16 genes, we
used quantitative Real-time PCR (qPCR) and subsequent
confirmation of the gene product by DNA sequencing.
Cellular location (A) and functional groups (B) of the mRNA Affy_IDs from adult dorsal root ganglia 7 days post spared nerve  injury Figure 2
Cellular location (A) and functional groups (B) of the mRNA Affy_IDs from adult dorsal root ganglia 7 days 
post spared nerve injury. Unknown refers to those Affymetrix entries that are either unknown genes or expressed sequences 
tag (ETS) that correspond to "transcribed loci" and "similar-to-genes" mRNAs.Molecular Pain 2009, 5:70 http://www.molecularpain.com/content/5/1/70
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Figure 3 shows the microarray plot and its counterpart
qPCR validation graph for each of the 16 selected
Affy_IDs. The qPCR validation shows that the selected
genes are differentially regulated in the adult SNI group
but many were also regulated in the young SNI group.
Overall, 15 genes were upregulated and only 1 gene was
downregulated following SNI when compared to sham
groups (ANOVA p < 0.001). The 15 upregulated genes
were classified into four groups according to the relative
expression of the adult versus the young SNI group (Tukey
or SNK test p < 0.05) (Figure 3A-D, bar charts). These four
groups were A: Genes preferentially expressed in adult
SNI: SERPINA3N, SERPINB2, IL-6 and MMP3, B: Genes
preferentially expressed in young SNI: CASPASE 3, TLR4,
CLIC-1 and MMP16, C: Genes equally expressed in both
adult and young SNI: CREM, MCP-1, MAOA, IPTKC and
CSF1; and D: Genes specific to the young SNI group:
P2RY14 and C3. The fifth group, E, comprises the only
downregulated gene, MAP2K6, when compared to the
sham groups (ANOVA p < 0.001) (Figure 3E). MAP2K6
was also down regulated in the adult SNI group when
compared to the young SNI group (Tukey p < 0.05).
Immunohistochemical analysis highlights differences in the 
cellular immune response to nerve injury in young and 
adult in the DRG
Since many of the differentially regulated genes between
young and adult SNI were related to the immune system,
Table 2: Summary of putative new gene candidates implicated in the neuropathic pain model SNI at the dorsal root ganglia level.
Affymetrix ID Gene Name Gene Symbol Group Functionality
1368224_at Serine (or cysteine) peptidase inhibitor, clade 
A, member 3N
SERPINA3N IS Inflammation [59-61]
1369191_at Interleukin 6 IL-6 IS Macrophage in neuropathic pain, inflammation [35]
1379631_at Colony stimulating factor 1 (macrophage) CSF-1 IS Specific factor for macrophages [73-75]
1387982_at Toll-like receptor 4 TLR4 IS Inflammation/Immune response/pain [46,47]
1368000_at Complement component 3 C3 IS Apoptosis, caspase activation, complement 
activation, pain processes [50-52]
1367973_at Macrophage chemoattractant protein-1 MCP-1/CCL2 IS Chemoattractant, pain processes [41-43]
1370449_at Purinergic receptor P2Y, G-protein 
coupled, 14
P2RY14 IS Immune response [49]
1375633_at Chloride intracellular channel 1 CLIC-1 IS Cell cycle progress/Microglia activation [48]
1387690_at Caspase 3 CASP3 Apop Apoptosis, inflammation, pain processes [76-78]
1373623_at Inositol 1,4,5-trisphosphate 3-kinase C ITPKC ST Ca2+ homeostasis [69,79]
1387809_at Mitogen-activated protein kinase kinase 6 MAP2K6 ST Modulation of p38 MAPK [62]
1369737_at cAMP responsive element modulator CREM RNA
mod
Crem isoform, c-fos regulation, expressed after 
thermal stimulation [68]
1370678_s_at Monoamine oxidase A Maoa NS p38/caspase 3 apoptosis pathways [63]
1368657_at Matrix metallopeptidase 3 MMP3 Other Remodellation, lymphocytes signalling, inflammation, 
pain processes [57,80,81]
1368590_at Matrix metalloproteinase 16 MMP16 Other Matrix remodelling [54,82]
1368487_at Serine (or cysteine) proteinase inhibitor, 
clade B, member 2
SERPINB2 Other Expressed by DRGs after injury [83]
The table shows the identified gene by Affy_ID, name, gene symbol, Go term classification group and its putative function. IS: immune system; Apop: 
apoptosis; ST: signal transduction; NS: nervous system; RNA mod: RNA modulation.Molecular Pain 2009, 5:70 http://www.molecularpain.com/content/5/1/70
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Microarray and quantitative Real-time PCR (qPCR) validation of genes differentially regulated in the dorsal root ganglia 7 days  after SNI surgery Figure 3
Microarray and quantitative Real-time PCR (qPCR) validation of genes differentially regulated in the dorsal 
root ganglia 7 days after SNI surgery. The figure shows microarray plots of the selected Affy_IDs and counterpart graphs 
of qPCR validation of the corresponding gene. For clarity, genes have been grouped into A) 'preferentially expressed in adult 
SNI', B) 'preferentially expressed in young SNI', C) 'genes equally expressed in both adult and young SNI groups', D) 'genes spe-
cific to young SNI' and E) 'downregulated gene group'. In the microarray plots, the y-axis indicates the normalised log2 value of 
expression and each point represents the level of a particular Affy_ID in a single array. In the qPCR validation graphs, the y-axis 
indicates the mean fluorescence intensity (± standard error). White: Adult sham rats (AHI); Blue: Adult SNI rats, contralateral 
(ADC); Purple: Adult SNI rats, ipsilateral (ADI); Pink: Young sham rats (PHI); Yellow: young SNI rats, contralateral (PDC); 
Grey: Young SNI rats, ipsilateral (PDI). For each gene, an ANOVA was performed and p < 0.001. * represent the differences 
with all experimental groups p < 0.05 in a 'post-hoc' Tukey test or SNK-test, power>80%.Molecular Pain 2009, 5:70 http://www.molecularpain.com/content/5/1/70
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we compared the cellular neuroimmune reaction in the
DRG following nerve injury at the two ages. We hypothe-
sised that if the differing patterns of gene regulation had
functional implications we might see differences in injury
induced reactions of the major cellular component of the
immune system in peripheral ganglia, the macrophages.
To determine macrophage reactions in the DRG after
nerve injury we immunostained them with the macro-
phage marker IBA-1 in combination with selective mark-
ers of subpopulations of DRG sensory neurons, NF200
(for A-neurons), CGRP and IB4 (for C-neurons), 7 days
following SNI surgery in young and adult rats (Figures 4,
5 and 6).
Figure 4 shows the striking macrophage response in adult
rats 7 days post SNI surgery. Macrophages can be seen (in
red) clustering around neuronal cell bodies in characteris-
tic 'ring-like' structures with processes extending from
their enlarged cell bodies towards neurons (Figure 4A
pink arrows). Figures 4B and 4C show that the macro-
phages are selectively clustered around the large A-neu-
rons which are stained with the marker NF200 (in green)
(Figure 4B, pink arrows) and not around the C-neurons
(Figure 4, blue arrows). We have confirmed these results
by double labelling IBA-1 +ve macrophages in these 'ring-
like structures with CD68/ED-1, another specific marker
of macrophages [22] (additional file 4). NG2, on the
other hand, a specific marker of satellite cells [23], did not
overlap with IBA-1(additional file 5). As C-neuron immu-
nomarkers are down-regulated after nerve injury [24-26],
these could not be used to quantify macrophage cluster-
ing, but instead neuronal diameter was used, The analysis
showed that 'rings' of macrophages are preferentially (p <
0.01, t-test) located around large (> 25 μm) NF200 +ve A-
neurons and that smaller (< 25 μm) C-neurons are rela-
tively free of macrophages. Figure 4D shows that 37.6% of
neurons from adult DRG have macrophage rings around
them 7 days post SNI (n = 660 cells pooled from 3 ani-
mals). Of these, 31.2% surround large A-neurons while
6.4% surround small C-neurons.
To investigate whether macrophage reactivity was
restricted to neurons whose axons were directly damaged
in the SNI surgery or whether neurons with 'spared' intact
axons also display 'rings' of macrophages, we distin-
guished damaged from non-damaged neurons in adult L4
and L5 DRG using a retrograde tracer. Fluorogold was
injected into the injured nerves (tibial and common pero-
neal) at the time of surgery and subsequently counter-
stained with the neuronal markers NF200, IB4 or CGRP
(Figure 5A). We then counted 'ring-like' structures around
damaged and non-damaged neurons and correlated the
data with cell body diameter. Of the total population of
large A-neurons in adult L4 and L5 DRGs, 7 days post SNI,
52.8% were damaged (Fluorogold +ve) and 47.2% were
non-damaged (Fluorogold -ve) (n = 559 A-neurons form
n = 3 animals). The data shows that the proportion of
'ring-like' structures in damaged A-neurons is significantly
greater than in undamaged A-neurons: 33.8% of damaged
A-neurons have 'ring-like' structures compared to 9.9% of
the non-damaged A-neurons (Figure 5B) (ANOVA p <
0.001). In contrast, only 10% of the damaged C-neurons
have 'ring-like' structures, while the non-damaged C-neu-
rons have none (Figure 5C) (n = 284 C-neurons pooled
form from 3 animals).
In young DRGs, however, the macrophages rarely formed
'rings' around neurons but remained scattered throughout
the DRG (Figure 6A, white arrows). Thus, the distribution
of macrophages in DRGs from young rats subjected to SNI
surgery resemble that of adult and young sham groups
with small cell bodies and few processes (Figure 6A white
arrows). Figure 6B shows that only 11.7% of large A-neu-
rons have macrophage 'ring-like' formations in the young
SNI group, which although significantly greater than
sham (1-2%), is significantly less than the adult SNI
group, where 43.7% of the large A-neurons display 'rings'
of reactive macrophages (ANOVA, p < 0.001; SNK p <
0.05, n = 2219 A-neurons from 3 animals, Figure 6B). Fig-
ure 6C compares the damaged and non-damaged neuro-
nal groups in adult and young rats with SNI surgery.
While in adult DRGs the macrophage 'ring-like' structures
occur in 33.8% of damaged large A-neurons and 9.9% of
non-damaged A-neurons, in young DRGs, significantly
fewer A-neurons have macrophage 'ring-like' structures
(10.6% of damaged, 1.1% of non-damaged) (Figure 6C).
(n = 559 A-neurons from 3 animals).
Discussion
In this study, we have used differential Affymetrix screen-
ing to examine age-related differences in transcriptional
changes in the dorsal root ganglion (DRG) of young and
adult rats after partial nerve damage "spared nerve injury"
model [16]). The study was triggered by the absence of
neuropathic behaviour following nerve injury in young
rats and humans in contrast to the hypersensitivity and
spontaneous pain that develops after adult nerve injury
[1]. Our results show a very high level of transcriptional
activity in DRGs following nerve injury in adulthood
compared to nerve injury in early life. Validation experi-
ments provided a list of genes, normally implicated in the
regulation of the immune system (Table 2), which have a
specific and different pattern of expression in the DRGs of
adults and young rats. We have also used immunohisto-
chemical analysis to reveal a major differential reactivity
in DRGs macrophages, the cellular component of
immune responses. Reactive macrophages cluster in a
characteristic display around the large A-neurons in adult
neuropathic DRGs while little difference is found in the
pattern of macrophages in young rats. Together, ourMolecular Pain 2009, 5:70 http://www.molecularpain.com/content/5/1/70
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Reactive macrophages in L4/L5 adult rat dorsal root ganglia 7 days after spared nerve injury Figure 4
Reactive macrophages in L4/L5 adult rat dorsal root ganglia 7 days after spared nerve injury. The immunohisto-
chemistry shows A) macrophages (IBA-1 marker, in red) forming clusters around the large (>25 μm) A-neurons (pink arrows), 
but not around small C-neurons (blue arrows); B) the same sections stained with NF200 (in green) to show A-neurons, the 
yellow arrow indicates a large A-neuron without macrophages; C) the merged image of IBA-1 and NF200 staining clearly 
shows the 'ring-like' structure of macrophages surrounding the A-neurons (pink arrows), while the small C-neurons (< 25 μm) 
has no macrophage ring (blue arrows); D) a graph showing the percentage of macrophage 'ring-like' formations in DRG neu-
rons 7 days post SNI according to large and small sensory neurons. *: Statistical significance between A- and C-neurons is indi-
cated (t-test, p < 0.001; n = 660 cells, pooled from 3 animals; power> 80%); SE: standard error, scale bar: 100 μm.Molecular Pain 2009, 5:70 http://www.molecularpain.com/content/5/1/70
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Analysis of the macrophage invasion of adult dorsal root ganglia 7 days after spared nerve injury Figure 5
Analysis of the macrophage invasion of adult dorsal root ganglia 7 days after spared nerve injury. Fluorogold 
(FLG, blue) was used as a retrograde tracer injected at the site of nerve injury, to label damaged neurons. A) Macrophages 
(IBA-1 positive, in red) surround large A-neurons (> 25 μm and NF200 +ve, in green) and are distributed as a 'ring-like' struc-
tures. The macrophages have large cell bodies and processes directed toward the damaged neurons (yellow arrows) and 
undamaged neurons (red arrow). The left panel shows that these 'ring-like' structures surround the many of Fluorogold 
labelled A-neurons (yellow arrows). Some non-Fluorogold labelled (undamaged) A-neurons are also surrounded by macro-
phages (red arrow) but others are not (pink arrow). The small diameter (< 25 μm) C-neurons (middle panel: non peptidergic, 
IB4 +ve, or right panel: peptidergic, CGRP +ve; both in green) do not generally display ring-like displays of macrophages (white 
arrows) although there are some exceptions (blue arrow). Scale bar: 100 μm. B) Graph showing the relative proportion of 
damaged (Fluorogold +ve) or undamaged A-neurons (> 25 μm) with macrophage rings (n = 559 A-neurons from 3 animals). C) 
Graph showing the relative proportion of damaged (Fluorogold +ve) or undamaged in C-neurons (< 25 μm) (n = 284 C-neu-
rons, from 3 animals). Statistical significance is indicated by * (ANOVA p < 0.001, SNK p < 0.05, power>80%). Grey boxes indi-
cate damaged neurons; white boxes indicate non-damaged neurons. Lines indicate the statistical differences between the 
several experimental groups. SE: standard error.Molecular Pain 2009, 5:70 http://www.molecularpain.com/content/5/1/70
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The effect of postnatal age on the distribution of macrophages in the dorsal root ganglia after spared nerve injury (SNI) Figure 6
The effect of postnatal age on the distribution of macrophages in the dorsal root ganglia after spared nerve 
injury (SNI). A) Shows large A-neurons (in red, NF200 +ve cells) and macrophages (in green, IBA-1 +ve) in adult or young 
rats in sham and injured groups (7 days after nerve injury). Both young and adult sham groups have inactivated macrophages 
(white arrows). In contrast, in adult animals post injury, the macrophages have large cell bodies (blue arrows) which form a 
'ring-like' structure that surround the large, injured A-neurons. The majority of non-injured neurons do not have these rings 
(yellow arrow). In young SNI animals (P10, 10 days old at the time of nerve injury) the macrophage distribution is similar to the 
sham groups (white arrows) with a small increase in 'ring-like' structures which is only significant when compared to the sham 
groups. B) Counts of 'ring-like' structures in young and adult DRG 7 days post SNI surgery. PI: ipsilateral SNI surgery at 10 days 
old; PH: sham at 10 days old, AI: ipsilateral to SNI surgery in adult; AH: sham in adult. *: indicates statistically significance when 
compared to the sham groups; #: indicates statistical significance when compared to all experimental groups (ANOVA p < 
0.001; SNK p < 0.05; n = 2219 A-neurons from 3 animals; power>80%). C) Counts of 'ring-like' structures in damaged or non-
damaged neurons in adult and young SNI operated animals. A preferential attraction of macrophages towards damaged large A-
neurons is evident in the adult SNI group. P-non: non damaged A-neurons in young rats; P-injury: damaged A-neurons in young 
rats; A-non: non damaged A-neurons in adult rats; A-injury: damaged A-neurons in adult rats. Fluorogold (in blue) was used as 
a retrograde tracer injected at the site of the injury, to label damaged neurons. #: indicates statistical significance in all experi-
mental groups (ANOVA p < 0.001; SNK p < 0.05; n = 559 A-neurons from 3 animals; power>80%) *: indicates statistical signif-
icance (t-test p < 0.005) when an independent t-test was performed on the young groups only (dashed lines). SE: standard 
error. Scale bar: 100 μm.Molecular Pain 2009, 5:70 http://www.molecularpain.com/content/5/1/70
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results suggest a strong correlation between the regulation
of the peripheral nervous system immune system and the
progression towards neuropathic pain.
The microarray analysis results provided 206 candidate
genes that were statistically significantly regulated in adult
rats only. Intriguingly, only 3 genes were differentially reg-
ulated in young animals after nerve injury and no overlap
was observed between the two age groups. The absence of
neuropathic pain behaviour at 7 days post nerve injury in
young rats [4,5] correlates with this low level of differen-
tially modulated genes in the young rat DRGs at the same
time point.
On validating those Affy_IDs related to adult neuropathic
pain, we found that most genes were closely related to the
immune system/inflammation, followed by genes related
to signal transduction, the nervous system and RNA/DNA
modulation. It is important to note that the highest pro-
portion (39%) of Affy_IDs (82 entries) belong to a group
of unknown "transcribed loci" or "EST" (Expressed
Sequence Tags). Other microarray analyses of the DRG
transcriptome have highlighted the differential regulation
between different experimental neuropathic models using
total or partial axotomy [27-30]. Here we present a whole
new set of "molecular tools" as new targets to dissect out
the peripheral mechanisms in the 'spared nerve injury'
model of neuropathic pain.
Several (16 Affy_IDs) of the top gene candidates from the
microarray analysis were validated using quantitative real-
time PCR (qPCR). Interestingly, the majority of these
genes (15 Affy_IDs) were also differentially regulated in
young animals after nerve injury. The difference between
the initial microarray results and the qPCR data arises
because microarray studies show widespread variations,
even under the same experimental conditions and it is
essential that the results are confirmed by other independ-
ent methods [31]. Thus, qPCR highlights small differences
not recognised by microarray technology. In addition, our
gene lists were subjected to a stringent p-value correction
for "false discovery rate" in the Limma test, designed to
minimize false positive candidates [32]. Overall these
results suggest that the young DRG is not simply regulat-
ing the same genes less efficiently than in the adult but
rather there is a different pattern of regulated genes in
early life.
Our data reveals an interesting set of genes which are
implicated in the modulation of the immune system.
Thus, we have found a set of chemokines which are upreg-
ulated in the dorsal root ganglia after SNI nerve injury
such as interleukin-6 (IL-6), macrophage chemoattractant
protein-1 (MCP-1/CCL-2), colony-stimulating factor 1
(CSF-1) and complement component 3 (C3). Proinflam-
matory cytokines have a recognized role in neuropathic
pain [33]. Particularly well-studied is IL-6, which is upreg-
ulated in the DRG following chronic constriction injury
and when blocked by minocycline reverses hyperalgesia
and allodynia [34]. IL-6 is upregulated in several microar-
ray analyses of other models of axotomy [27,30] and is
associated with macrophage invasion in peripheral nerve
[35]. Spinal administration of IL-6 has anti-nociceptive
effects in the spinal nerve ligation neuropathic pain
model measured by a dose-related inhibition of electri-
cally evoked C-fibre activity [36]. MCP-1 is a chemokine
that plays a role in the recruitment of monocytes to sites
of injury and infection [37] and a role in pain processes
[38]. Exogenous administration of MCP-1 is known to
depolarize and evoke action potential activity in DRG
[39] and to excite cultured neonatal DRG neurons and to
promote the secretion of the neuropeptides, substance P
and CGRP [40,41]. Moreover, MCP-1 receptor CCR2
knockout mice fail to develop mechanical allodynia after
nerve injury [38]. As for immune system activation and
recruitment, MCP-1 is associated with both resident spi-
nal microglia and infiltrating macrophages [42] and
CCR2 null mice do not develop microglial activation [43].
Nerve injury promotes the expression of MCP-1 in DRG
cells [44] and it is possible that it is released centrally in
neuropathic pain states. CSF-1 also has a role in microglia
activation [45]. The upregulation of these three genes
observed here in the DRG suggests a similar role as
described in the spinal cord. Since macrophage activation
in the DRG after nerve injury is greater in adult than in
young SNI rats, chemokine modulation could be a key
factor underlying the different neuropathic pain behav-
iour at the two ages.
Other validated genes support the role of macrophage
activation in adult DRGs, such as toll-like receptor 4
(TLR4) [46,47] and the chloride intracellular channel 1
(CLIC-1) [48]. Interestingly, in young injured DRGs we
have found other markers related to macrophage activity
such as the chemotactic purinergic receptor P2Y, G-pro-
tein coupled 14 [49] and complement component 3 [50-
52] suggesting a differential macrophage activity, rather
than simple absence of activity through the postnatal
development.
A further group of regulated genes in DRGs after nerve
injury have a general role in regulating the extracellular
matrix environment. Thus, matrix metallopeptidases 3
and 16, (MMP3 and MMP16) are proteoglycanases capa-
ble of degrading the major components of the extracellu-
lar matrix [53,54] and are related to macrophage invasion
[55]. Recent studies have shown that other metalloprotei-
nases, MMP2 and MMP9 contribute to the allodynia that
follows neuropathy [56]. MMP3 has recently been impli-
cated in the inflammatory response [57] and the immune
reaction in some neuropathies [58]. Possibly counteract-
ing the metalloproteinases, we found two genes: serineMolecular Pain 2009, 5:70 http://www.molecularpain.com/content/5/1/70
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(or cysteine) inhibitor, clade A, member 3N (Serpin A3)
and serine (or cysteine) inhibitor, clade B, member 2 (Ser-
pin B2) that are implicated in protease inhibition and
inflammation [59-61] which are specific for the adult SNI
group. This data suggest that the balance of these particu-
lar MMPs and Serpins may be essential for macrophage
invasion in the DRGs after nerve injury.
The final group of validated genes was related to intracel-
lular signalling pathways such as Mitogen-activated pro-
tein kinase kinase 6 (MAP2K6) and Monoamino oxidase
A (MAOA) which are related to the modulation of the p38
pathway [62,63]. The p38 pathway has a role in microglia
activation in the spinal cord [33,64] and so this data sug-
gests two new putative candidate targets for macrophage
modulation as part of the p38 cascade of activation. Cas-
pase 3, known to be involved in apoptosis [65] and cell
loss [66] and TLR4 modulation [67] are upregulated in
both adult and young SNI group, which is consistent with
the stress produced by the nerve injury. cAMP responsive
element modulator (CREM) isoform (ICER) has a dem-
onstrated role in c-fos regulation after thermal stimula-
tion and its overexpression represses the c-fos and c-jun
promoters and attenuates early gene induction following
noxious stimulation [68]. Inositol 1,4,5-trisphosphate 3-
kinase C (ITPKC) has been implicated in Ca2+ homeosta-
sis and T lymphocytes activity [69], its upregulation after
the nerve injury suggests a possible role in the lymphocyte
signalling.
Our microarray analysis highlights the importance of the
immune system in the SNI neuropathic model and cor-
roborates the relationship between the activation of both
microglia and macrophages and neuropathic pain behav-
iour [9,14]. Nevertheless, it is clear that neuropathic pain
behaviour is not simply a result of macrophage activation:
some genes related to macrophage/microglia reactivity are
upregulated in young rats after nerve injury despite the
fact that they have no neuropathic pain response [4].
Immunohistochemical analysis suggests that equally
important is the pattern of macrophage response: in the
adult rat post injury, activated macrophages take on a
characteristic [70,14] distribution throughout the DRGs,
selectively surrounding the large A-neurons in a 'ring-like'
structures. In contrast, macrophages in young rats post
injury do not form these 'ring-like' structures and are not
selectively recruited to the injured A-neurons. This obser-
vation suggests that the failure of macrophages in young
animals to be attracted toward damaged A-neurons could
be a key factor responsible for the lack of neuropathic
behaviour. This could be due to the absence of released
macrophage activation/chemoattractant factors. Our
results are consistent with those of, Murphy et al, 1996
who described the presence of IL-6 in large and medium
size neurons in axotomized adult DRGs [71]. Hence, the
immature neuroimmune response to nerve injury and the
consequent lack of neuropathic pain in young mammal
may not be due to a deficient immunological capacity per
se but to antigenic inexperience [72] which leads to mac-
rophages failing to specifically target neurons in the
DRGs.
Conclusions
Differential microarray analysis has revealed clear differ-
ences in the response in the dorsal root ganglia to periph-
eral nerve injury in adult and young rats which are likely
to underlie the known age related differences in the onset
of neuropathic pain. Genes involved in the immune sys-
tem, many of which play a role in macrophage activity, are
the most differentially regulated group following adult
nerve injury relative to the younger animals. Consistent
with this, macrophages are activated in the adult DRGs, in
a characteristic pattern around large A sensory neurons
following nerve injury but this pattern of activation does
not occur in young rats. This study highlights the impor-
tant contribution of the maturity of the immune system
and neuron/macrophage interactions to the postnatal
development of neuropathic pain.
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Additional file 1
Colocalisation of ATF-3 and Fluorogold in damaged neurons of adult 
DRGs. To quantify damaged neurons we used the retrograde tracer Fluor-
ogold (see 'Methods' sections). The figure represents the validation of our 
technique. ATF-3 (in red), is a marker of neuronal damage [18] and 
overlaps with Fluorogold staining (in blue) in 92.4% (± 1SE) of the neu-
rons. Yellow asterisks indicate colocalisation of ATF-3 and Fluorogold; 
white asterisks indicate undamaged neurons with no immunoreactivity for 
both markers. Confocal images; optical sections: 0.8 μm, Scale bar: 30 
μm.
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Macrophage ring formation around adult DRGs neurons 7 days after 
nerve injury. A-D) show reactive macrophages in adult nerve damaged 
DRGs which upregulate and coexpress the specific macrophage markers 
CD68/ED-1 (in green, A) and IBA-1 (in red, B). These macrophages 
(white arrow heads) infiltrate and form a 'ring-like' structure around the 
damaged neurons which are shown in (C) in blue, labelled with Fluoro-
gold. (D) Note the colocalisation of the CD68 and IBA-1(in yellow) in 
the macrophage ring formations. (E & F) In adult sham DRGs, the mac-
rophages (yellow arrow heads) are not stained with CD68 (in green) 
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focal images; optical sections: 0.8 μm, Scale bar: 30 μm.
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Satellite cells and macrophage staining in adult DRGs. The satellite 
cells (yellow arrow heads) are labelled with the specific marker NG2 (in 
green, A, D, E and G) and the macrophages (white arrow heads) with 
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distinctive markers of satellite cells (NG2) and macrophages (IBA-1). A 
- D show cells from adult DRGs after nerve injury. C) shows neurons 
labelled with the retrograde tracer Fluorogold (in blue) which are sur-
rounded by infiltrated macrophages (B and D). E - G show cells from 
adult sham DRGs where the macrophages have small cell bodies and are 
scattered through the section. Confocal images; optical sections: 0.8 μm, 
Scale bar: 30 μm.
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